Y-mAbs Therapeutics’ (YMAB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research note published on Wednesday morning,Benzinga reports.

YMAB has been the subject of several other research reports. Canaccord Genuity Group raised shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. Wedbush reissued an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. BMO Capital Markets cut their target price on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. Finally, Morgan Stanley decreased their target price on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $20.89.

Y-mAbs Therapeutics Trading Down 3.5 %

Shares of Y-mAbs Therapeutics stock opened at $9.43 on Wednesday. The stock has a market capitalization of $422.36 million, a price-to-earnings ratio of -17.46 and a beta of 0.61. Y-mAbs Therapeutics has a 1-year low of $6.09 and a 1-year high of $20.90. The firm’s 50-day moving average price is $12.87 and its two-hundred day moving average price is $12.67.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. During the same quarter in the previous year, the company posted ($0.18) earnings per share. As a group, equities research analysts predict that Y-mAbs Therapeutics will post -0.66 EPS for the current year.

Insider Buying and Selling at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the transaction, the insider now directly owns 67,681 shares of the company’s stock, valued at $877,822.57. The trade was a 30.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 22.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at $44,000. China Universal Asset Management Co. Ltd. lifted its stake in Y-mAbs Therapeutics by 66.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after acquiring an additional 3,416 shares during the period. Intech Investment Management LLC bought a new position in Y-mAbs Therapeutics during the 3rd quarter valued at about $133,000. SG Americas Securities LLC purchased a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at about $178,000. Finally, Empire Financial Management Company LLC purchased a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at about $210,000. 70.85% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.